糖尿病肾病临床分子标志物研究进展

发布时间：2018-02-13 12:17

本文关键词： 糖尿病肾病组学分子标志物　出处：《中国实用内科杂志》2017年03期 　论文类型：期刊论文

【摘要】：糖尿病肾病(diabetic nephropathy,DN)是导致终末期肾脏疾病的最主要原因,占透析人群的25%~45%。30%~40%的1型糖尿病及30%的2型糖尿病患者最终会发展成为DN。蛋白尿和估算肾小球滤过率(estimated glomerular filtration rate,e GFR)是目前临床中最常用的DN诊断和预后判断标志物,但其缺乏足够的敏感性和特异性。近年来,有研究在不断地寻找新型DN早期诊断和预后判断的分子标志物。新的研究方法,如基于多组学图谱的生物标志物研究,通过利用不同阶段DN患者生物样本,寻找和验证新的分子标志物,这不仅可以进一步阐明DN分子机制,并且有助于构建DN分子诊断体系,提高DN诊治水平,改善患者预后。而一些新发现的DN分子标志物,仍需要利用大样本的前瞻性研究,证实其临床转化应用价值。文章就近年来DN分子标志物研究进展以及相关研究策略进行总结。
[Abstract]:Diabetic nephropathy (DN) is the leading cause of end-stage renal disease. The patients with type 1 diabetes (40%) and type 2 diabetes (30%%), who account for 40% of the dialysis population, will eventually develop into DN.proteinuria and estimate the glomerular filtration rate (GFRs), which are the most commonly used markers for the diagnosis and prognosis of DN. However, it lacks sufficient sensitivity and specificity. In recent years, there have been studies looking for new molecular markers for early diagnosis and prognostic judgment of DN. New research methods, such as biomarkers based on multiple sets of maps, By using biological samples of DN patients at different stages, we can find and verify new molecular markers, which can not only further elucidate the molecular mechanism of DN, but also contribute to the construction of DN molecular diagnostic system and improve the level of DN diagnosis and treatment. In order to improve the prognosis of patients, some newly discovered molecular markers of DN still need to use a large sample of prospective studies to confirm the value of clinical transformation. This article summarizes the research progress and related research strategies of DN molecular markers in recent years.
【作者单位】：国家肾脏疾病临床医学研究中心南京总医院南京大学医学院;
【分类号】：R587.2;R692.9

【相似文献】